Avantor and Catalent Enter Multi-Year Agreement

Article

Avantor and Catalent have entered into a multi-year supply and services agreement.

Avantor announced on Jan. 9, 2023 that it has entered into a multi-year supply and services agreement with Catalent. Under the agreement, Avantor will become the primary supplier of a broad range of laboratory supplies, clinical and productions materials, and services to Catalent. The agreement will expand the companies’ existing relationship and offer more choices to customers.

"We have seen firsthand that Avantor is a terrific partner that brings diverse capabilities and expertise across modalities and geographies, which is essential to meeting global health needs," said Alessandro Maselli, president and CEO, Catalent. "We look forward to deepening our work with the Avantor team to bring current and novel treatments to patients around the world."

"Catalent has built tremendous global capabilities and a reputation as a trusted collaborator to pharma, biotech, and consumer health partners throughout the development and production lifecycle," said Michael Stubblefield, president and CEO, Avantor. "We are pleased to expand our support for Catalent and enable efficiencies to accelerate science for their customers around the globe."

Source: Avantor

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content